Esketamine Regulates Mitophagy through ULK1/FUNDC1 Signaling Pathway to Improve LPS-induced Acute Respiratory Distress Syndrome.
Current Pharmaceutical Design February 28, 2025 Mei Ding, Ping Pei, Weihua Liu et al. 3 citations
As a heterogeneous clinical syndrome, acute respiratory distress syndrome (ARDS) is caused by infection-associated inflammation with limited treatment options. Esketamine possesses antiinflammatory properties, and it is effective in treating lung diseases. This study aimed to unveil the efficacy and mechanism of esketamine in ARDS. Lipopolysaccharide (LPS) is widely used to induce inflammatory...